Avalyn Pharma Inc.
Avalyn Pharma Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|
Assets | ||||||
Assets Current | ||||||
Cash And Cash Equivalents At Carrying Value | 92 | |||||
Marketable Securities Current | 31 | |||||
Prepaid Expense And Other Assets Current | 7 | |||||
Assets Current | 130 | |||||
Assets Noncurrent | ||||||
Property Plant And Equipment Net | 1 | |||||
Operating Lease Right Of Use Asset | 1 | |||||
Other Assets Noncurrent | 3 | |||||
Assets Noncurrent | 6 | |||||
Assets | 136 | |||||
Liabilities And Stockhold… | ||||||
Liabilities Current | ||||||
Accounts Payable Current | 3 | |||||
Accrued Liabilities Current | 8 | |||||
Operating Lease Liability Current | 1 | |||||
Liabilities Current | 12 | |||||
Liabilities Noncurrent | ||||||
Long Term Debt Noncurrent | 15 | |||||
Operating Lease Liability Noncurrent | 1 | |||||
Liabilities | 28 | |||||
Temporary Equity | ||||||
Stockholders Equity | ||||||
Common Stock Value | 0 | |||||
Additional Paid In Capital Common Stock | 28 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 0 | |||||
Retained Earnings Accumulated Deficit | -292 | |||||
Stockholders Equity | -264 | |||||
Liabilities And Stockholders Equity | 136 | |||||
Series C Preferred Stock | 0 | |||||
Preferred Stock Liquidation Preference Value | 373 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | |||||
Common Stock Shares Authorized | 585 | |||||
Common Stock Shares Issued | 1 | |||||
Shares Outstanding | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month |
|---|---|---|---|
| 2026 | 16.33% | 5.87% | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | |||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Avalyn Pharma Inc. (AVLN) — SEC Financial Statements & Analysis
Avalyn Pharma Inc. (AVLN) is a pharmaceutical preparations company, incorporated in DE. Avalyn Pharma Inc. trades on Nasdaq as: AVLN. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Avalyn Pharma Inc. reported a Debt-to-Equity ratio of -0.10x. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -0.10x
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Avalyn Pharma Inc. in?
Avalyn Pharma Inc. (AVLN) operates in the Pharmaceutical Preparations industry.
What exchange does AVLN trade on?
Avalyn Pharma Inc. (AVLN) trades on the Nasdaq.
Where is Avalyn Pharma Inc. incorporated?
Avalyn Pharma Inc. is incorporated in DE.